Imigran Sprint (Sumatriptan Succinate)

Sumatriptan binds to serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This triggers vasoconstriction of dilated intracranial vessels and blocks the release of inflammatory neuropeptides, which together reduce headache pain and associated migraine symptoms.

The specific dose and dosing schedule for Imigran Sprint are determined by the prescribing healthcare professional based on the patient’s clinical condition, age, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for sumatriptan in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified clinician.

To request Imigran Sprint, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Imigran Sprint belongs to the triptan class, which provides rapid, targeted relief by acting on serotonin receptors. Compared with non‑specific analgesics, triptans address the underlying vascular and neurogenic mechanisms of migraine, often achieving faster and more complete symptom resolution.

Imigran Sprint should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Imigran Sprint is taken orally as a tablet. The patient swallows the tablet whole with water, typically at the onset of a migraine attack. If needed, a second dose may be taken after a minimum interval as directed by the prescriber.

Serious risks include coronary artery spasm or myocardial infarction, severe hypertension, and serotonin syndrome, especially when used with other serotonergic agents. Patients with known cardiovascular disease or uncontrolled hypertension should avoid the medication.

Imigran Sprint is contraindicated in patients with a history of coronary artery disease, uncontrolled hypertension, hemiplegic or basilar migraine, and those currently taking MAO inhibitors. It should also be avoided in individuals with known hypersensitivity to sumatriptan or any excipients.